

Annual document pursuant to Section 10 of the German Securities Prospectus Act (“Wertpapierprospektgesetz” or “WpPG”)

Pursuant to Section 10 of the WpPG entered into force as from July, 1 2005, biolitec must at least once annually make available to the public a document containing or referring to all information which biolitec has published or made available to the public during the past twelve months. In the following document biolitec has summarized all information published or made available to the public in a so called annual document as specified in Section 10 Paragraph 1 of the WpPG for the period from July, 1 2006 until June, 30 2007.

Ad - hoc - Release (§15 WpHG)	Date of Release	Availability / Published in
biolitec AG increases fiscal year revenues about 17% to Euro 29.1 millions as well as operating profit about 90.7%	29.09.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG increases first quarter revenues about 30% - future area aesthetics successful	04.10.2006	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG commences contract negotiations with US biotech companies on out-licensing and clinical development of its cancer drug Foscan®	31.01.2007	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec AG revenue growth accelerates to 42 % in the second quarter 06/07 - EBIT increases to Euro 2.5 million in the first six months 06/07	28.02.2007	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec's confirmatory study for Foscan® successfully completed	16.04.2007	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec requests an immediate approvability meeting with the FDA for Foscan® in the US-market based on the very positive confirmatory study results	26.04.2007	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05
biolitec- earnings more than tripled to cumulated 3.7 million In the third quarter - revenue growth in the USA increased to + 83%	31.05.2007	http://www.biolitec.com/english/ir/adhoc.asp?m=ir&s=05

Press Release	Date of Release	Availability / Published in (Partly available in German)
Langjährige Krebspatientin in Spanien jetzt mit Foscan® - Therapie behandelt	03.08.2006	http://www.biolitec.de/german/news/pressreleases.asp?m=news&s=01
biolitec AG erzielt Rekordgewinn mit 2,3 Mio. Euro und steigert Umsatz auf 29,1 Mio. Euro - Starke Nachfrage im Zukunftsbereich ästhetische Behandlungen	29.09.2006	http://www.biolitec.de/german/news/pressreleases.asp?m=news&s=01
biolitec expandiert mit Geschäftsbereich Ästhetik – Umsatzsprung von mehr als 30 % im 1. Quartal 2006/2007	05.10.2006	http://www.biolitec.de/german/news/pressreleases.asp?m=news&s=01
Erfolgreiche Unternehmenspräsentation der biolitec auf dem Deutschen Eigenkapitalforum Herbst 2006	30.11.2006	http://www.biolitec.de/german/news/pressreleases.asp?m=news&s=01
biolitec's annual general meeting decides on share repurchase	14.12.2006	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0

		1
Prime Minister Dieter Althaus impressed of biolitecs' innovative research centre in Jena	18.01.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec AG commences contract negotiations with US biotech companies on out-licensing and clinical development of its cancer drug Foscan®	01.02.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec AG - study confirms very good results for cancer drug Foscan®	23.04.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec requests an immediate approvability meeting with the FDA for Foscan® in the US-market	27.04.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec's Foscan® is used in a clinical study for the treatment of localised carcinoma of the prostate	14.05.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
Strong demand for biolitec's laser for the treatment of benign prostate hyperplasia in the USA	25.05.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec - earnings more than tripled to cumulated 3.7 million in the third quarter - revenue growth in the USA increased to + 83%	31.05.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec develops new therapy for the reduction of abdominal fat - hope for people suffering from overweight to minimise visceral fat	21.06.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1
biolitec develops new therapy for the reduction of abdominal fat - hope for people suffering from overweight to minimise visceral fat	27.06.2007	http://www.biolitec.com/english/news/pressreleases.asp?m=news&s=0 1

Reports (Annual Financial Statement / Quarterly Reports)	Date of Release	Availability / Published in
--	-----------------	-----------------------------

Annual Report 2005/2006	29.09.2006	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06
3 Months Report	30.11.2006	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06
6 Months Report	28.02.2007	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06
9 Months Report	31.05.2007	http://www.biolitec.com/english/ir/reports.asp?m=ir&s=06

Annual General Meeting	(Only available in German)
------------------------	----------------------------

Einladung zur Hauptversammlung 2006 inklusive Tagesordnung	05.10.2006	http://www.biolitec.de/german/ir/generalmeeting.asp?m=ir&s=12
Geschäftsbericht 2005/2006	29.09.2006	http://www.biolitec.de/german/ir/reports.asp?m=ir&s=06
Einzelabschluss biolitec AG	29.09.2006	http://www.biolitec.de/german/ir/reports.asp?m=ir&s=06
Vollmacht für Stimmrechtsvertreter	05.10.2006	http://www.biolitec.de/german/ir/generalmeeting.asp?m=ir&s=12

Erklärung Dt. Corporate Governance Kodex	21.09.2006	http://www.biolitec.com/german/ir/corgov.asp?m=ir&s=08
Abstimmungsergebnisse	22.11.2006	http://www.biolitec.de/german/ir/generalmeeting.asp?m=ir&s=12
AR-Bericht für das Geschäftsjahr 05/06 gemäß § 171 Abs. 2 AktG	21.09.2006	http://www.biolitec.de/german/ir/reports.asp?m=ir&s=06
Bericht des Vorstandes zu TOP4 der Hauptversammlung vom 21.11.2006	21.09.2006	http://www.biolitec.de/german/ir/generalmeeting.asp?m=ir&s=12
Bestätigungsvermerk des Wirtschaftsprüfers zum Jahresabschluss	21.09.2006	http://www.biolitec.de/german/ir/reports.asp?m=ir&s=06

Release of a voting rights announcement according to article 41 section 2 respectively 4a WpHG:	Date of Release	Availability /
Voting rights announcement according to article 41 section 4a Sentence 1 respectively 2 WpHG	21.01.2007	www.dgap.net
Correction release of a voting rights announcement according to article 41 section 2 respectively 4a WpHG	16.02.2007	www.dgap.net

Disclosure of securities transactions - Notifications pursuant to section 15a WpHG	Date of Release	Availability / Published in
-	-	-

Other Documents	Date of Release	Availability / Published in (Only available in German)
Concord Equity Research	04.07.2006	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11
Concord Equity Research	18.10.2006	http://www.biolitec.com/german/ir/coverage.asp?m=ir&s=11
"Börsenbrief Nebenwerte Insider" - GSC Research: Methode zur Cellulite-Bekämpfung eröffnet riesiges Marktpotenzial	18.12.2006	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11
„Neues Jahr, neuer Schwung?“ - Der Aktionär	16.01.2007	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11
TradeCentre Börsenbrief - biolitec:	08.03.2007	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11

Kampf gegen Cellulite und Fett! Unser Urteil: Kaufenswert!		erage.asp?m=ir&s=11
Concord Equity Research	13.03.2007	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11
Börse Online - Small Cap mit Potenzial	15.03.2007	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11
Concord Equity Research	11.06.2007	http://www.biolitec.de/german/ir/coverage.asp?m=ir&s=11